GraphWear Raises $20.5 Million Led by Mayfield to Develop the First No-Needle, No-Blood Approach to Disease Monitoring

GraphWear, the company pioneering needle-free disease monitoring, today announced $20.5 million in Series B funding for its first-of-its-kind disease management platform. GraphWear’s technology offers the first genuinely non-invasive method to map patient health without needles, blood or urine. With the power to modernize healthcare, the technology unlocks a new way to monitor and understand patient health. The round, led by Mayfield with participation from MissionBio Capital, Builders VC and VSC Ventures, will accelerate the development and scale of the platform for targets across diabetes, heart disease and cancer detection. 

Traditional methods of monitoring chronic conditions are often painful, inconvenient and cost-prohibitive for those who need consistent access to their health information, like diabetics. Only about 1% of the 450 million diabetics worldwide have access to a continuous glucose monitor (CGM) to track blood sugar levels in real-time, but the current needle-reliant method causes many people with diabetes to give up on monitoring altogether. 

The first no-needle, no-blood approach to disease monitoring
GraphWear’s sensor has the potential to change the way we monitor and understand patient health, with an all-new adherence to manage some of the most significant modern diseases. Using nanotechnology, the sensor measures molecules like glucose on the surface of the skin. It can then give an accurate read of glucose levels using as little as a few 100 glucose molecules. All of this is done painlessly, without breaking the skin, and with no needle, extraction or lab processing. 

With an accessible, easy-to-use form factor, the technology can provide insight into one’s health continuously, empowering patients and providers to make more informed decisions quickly and cost-effectively – without unnecessary tests or lengthy turnaround times at a lab. This level of insight can drive greater efficiency in healthcare from diagnosis and condition management through to treatment and care. 

Mapping human health for better care, from diagnosis to treatment
The company was founded by nanotechnology specialists Rajatesh Gudibande and Saurabh Radhakrishnan. While attending college in rural India, Gudibande contracted malaria, but with a lack of access to lab facilities, he faced misdiagnosis and limited treatment options. Recognizing the severe disparity in healthcare that comes from inaccessibility, Gudibande was inspired to create a new kind of system. 

“With GraphWear, we’ve sought to design a non-invasive solution, with low power requirements and a small form factor that opens up potential for monitoring health on a global scale,” explained President and Co-Founder Rajatesh Gudibande. “Through our partnership with world-class investors like Mayfield, we’re entering a new phase of development, to support patient lives and reinvent the way we understand and monitor health overall.” 

GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes. Beyond diabetes, the platform has the potential to monitor cholesterol levels for heart disease or even detect biomarkers for cancer. This latest round of funding will support the platform through clinical trials and drive its development as an extensible disease management platform. In tandem, GraphWear is growing its team, with plans to recruit across all areas of its business. 

“The vision of venture capital is to partner with pioneers who dream big and succeed in making a huge impact on humanity. That’s what we’ve found in our partnership with Rajatesh, Saurabh and the team at GraphWear,” said Ursheet Parikh, Mayfield Partner and Graphwear board member. “With regular, easy access to health information, Graphwear is building a platform that has the ability to evolve the way we track our health, detect patterns in disease and make more informed treatment decisions.” 

To learn more about how Graphwear is empowering broad access to health monitoring, visit here.

About Graphwear
GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear’s technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely health information in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer. The company has raised a combined $25 million from investors like Mayfield, MissionBio Capital, Builders VC and VSC Ventures. 
For more information, visit: www.graphwear.co.
 

Contact Information

Jacqueline Schneider

PR for GraphWear

VSC for GraphWear

Contact via E-mail